It's fair to say that Editas Medicine (EDIT 4.74%) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff. Despite its supposedly powerful gene-editing technology, the company is struggling to advance its clinical programs to the point where they might be commercialized and generate revenue.Thankfully for Editas shareholders, Vertex Pharmaceuticals (VRTX 1.15%) just gave the business a much-needed break -- one that might ev ...